AstraZeneca plc Company Profile (LON:AZN)

About AstraZeneca plc

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: AZN
  • CUSIP:
Key Metrics:
  • Previous Close: $65.42
  • 50 Day Moving Average: $4904.25
  • 200 Day Moving Average: $4264.96
  • 52-Week Range: £12,650,000 - GBX 3,680
  • Trailing P/E Ratio: 28.05
  • P/E Growth: 3.01
  • Market Cap: $62.10B
  • Outstanding Shares: 1,265,000,000
Additional Links:

Analyst Ratings

Consensus Ratings for AstraZeneca plc (LON:AZN) (?)
Ratings Breakdown: 5 Sell Ratings, 13 Hold Ratings, 11 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: GBX 4,915.68

Analysts' Ratings History for AstraZeneca plc (LON:AZN)
DateFirmActionRatingPrice TargetDetails
8/25/2016Berenberg BankSet Price TargetBuyGBX 5,550View Rating Details
8/25/2016Goldman Sachs Group Inc.Set Price TargetSellGBX 4,000View Rating Details
8/25/2016Beaufort SecuritiesReiterated RatingHoldView Rating Details
8/24/2016Shore CapitalReiterated RatingHoldView Rating Details
8/23/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 4,900View Rating Details
8/19/2016Morgan StanleyBoost Price TargetOverweightGBX 5,000 -> GBX 5,800View Rating Details
8/11/2016HSBCReiterated RatingHoldGBX 4,700View Rating Details
8/8/2016Jefferies GroupSet Price TargetNeutralGBX 5,400View Rating Details
8/8/2016Deutsche Bank AGReiterated RatingBuyGBX 5,800View Rating Details
8/2/2016BNP ParibasSet Price TargetBuyGBX 5,300View Rating Details
7/29/2016Credit Suisse Group AGReiterated RatingUnderperformGBX 4,000View Rating Details
7/29/2016Sanford C. BernsteinSet Price TargetNeutralGBX 5,168View Rating Details
7/28/2016Bryan, Garnier & CoReiterated RatingBuyView Rating Details
7/27/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
6/24/2016Independent Research GmbHSet Price TargetSellGBX 3,650View Rating Details
6/24/2016Societe GeneraleReiterated RatingBuyGBX 6,900View Rating Details
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details
4/25/2016Barclays PLCReiterated RatingEqual WeightGBX 5,000View Rating Details
4/14/2016Liberum CapitalReiterated RatingBuyGBX 5,300View Rating Details
3/24/2016NatixisReiterated RatingNeutralGBX 4,456View Rating Details
3/23/2016NomuraLower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details
1/13/2016Nordea Equity ResearchReiterated RatingHoldGBX 4,698.35View Rating Details
11/16/2015Kepler Capital MarketsReiterated RatingReduceGBX 3,700View Rating Details
7/14/2015DanskeUpgradeHoldGBX 4,400View Rating Details
4/9/2015Redburn PartnersUpgradeBuyView Rating Details
11/7/2014Cenkos Securities LtdReiterated RatingHoldView Rating Details
(Data available from 8/31/2014 forward)


Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by


Earnings Estimates for AstraZeneca plc (LON:AZN)
Current Year EPS Consensus Estimate: $4.08 EPS


Dividend History for AstraZeneca plc (LON:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2016GBX 68.701.37%8/11/20168/11/20169/12/2016
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for AstraZeneca plc (LON:AZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972
(Data available from 1/1/2013 forward)


Latest Headlines for AstraZeneca plc (LON:AZN)
DateHeadline logo[$$] Pfizer Buys Part of AstraZeneca's Antibiotics Business (LON:AZN) - August 24 at 11:55 AM logoETF’s with exposure to AstraZeneca Plc : August 24, 2016 (LON:AZN) - August 24 at 11:55 AM logoAstraZeneca plc (ADR)'s (AZN) Symbicort Gets New Life - TCC (LON:AZN) - August 23 at 3:43 PM logoIs AstraZeneca’s Valuation Improving Compared to Peers? (LON:AZN) - August 23 at 3:43 PM logoAstraZeneca Plc :AZN-GB: Earnings Analysis: Q2, 2016 By the Numbers : August 23, 2016 (LON:AZN) - August 23 at 6:13 AM logoLilly, AstraZeneca Alzheimer's drug fast tracked (LON:AZN) - August 22 at 8:31 AM logoLilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease (LON:AZN) - August 22 at 8:31 AM logo[$$] Eli Lilly, AstraZeneca Progress With Alzheimer's Drug (LON:AZN) - August 22 at 8:31 AM logo[$$] Pharmaceuticals: Staying power (LON:AZN) - August 21 at 3:39 PM logo[$$] The Profit and Peril of Cancer Drugs (LON:AZN) - August 19 at 4:23 PM logo3 Reasons Inovio Pharmaceuticals Inc. Stock Could Rise (LON:AZN) - August 19 at 12:04 PM logoAstraZeneca (AZN) Making New Innovation for COPD Patients (LON:AZN) - August 17 at 11:55 AM logoAstraZeneca plc (ADR) (AZN) Got Breakthrough In The UK Market - TCC (LON:AZN) - August 15 at 3:50 PM logoFTSE 100 struggles to stay on winning track (LON:AZN) - August 15 at 10:55 AM logoThese FTSE 100 stars have exploded in Q3! And they’re not finished yet (LON:AZN) - August 15 at 10:55 AM logoWill AstraZeneca plc (AZN) Survive Crestor Loss? - The Country Caller - TCC (LON:AZN) - August 13 at 3:42 PM logoAstrazeneca PLC (AZN) Shares are Up 0.41% - Trade Calls (LON:AZN) - August 10 at 8:29 AM logoAstraZeneca inhibitor trial fails to meet endpoint (LON:AZN) - August 9 at 4:48 PM
News IconUnsuccessful and disappointing clinical trials for AstraZeneca's lung cancer drug (LON:AZN) - August 9 at 4:48 PM logoCurrent Analysts Rating Update: Astrazeneca PLC (NYSE:AZN) , Juno Therapeutics, Inc. (NASDAQ:JUNO) - Street Updates (LON:AZN) - August 9 at 12:34 PM
News IconIs AstraZeneca PLC (NYSE:AZN), a large market cap stock a smart buy? (LON:AZN) - August 8 at 3:45 PM logoAstraZeneca plc (ADR) (AZN): Double Success in Oncology Portfolio Could Prove To Be Highly Lucrative (LON:AZN) - August 8 at 3:45 PM logoAnalysts Actions to Track: Astrazeneca PLC (NYSE:AZN) , Allergan plc. (NYSE:AGN) - Street Updates (LON:AZN) - August 8 at 8:31 AM
News IconToday's Top Gainers in the Market AstraZeneca PLC (NYSE:AZN) from Healthcare - The Daily Leicester (LON:AZN) - August 5 at 3:44 PM logoWhy AstraZeneca (AZN) Stock Is Higher Today (LON:AZN) - August 5 at 3:44 PM
News IconEarnings Expectations Overview: NVIDIA Corporation (NASDAQ:NVDA), AstraZeneca PLC (NYSE:AZN) - News Oracle (LON:AZN) - August 5 at 12:08 PM logoAstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woes (LON:AZN) - August 5 at 12:08 PM
News IconUpdate on AstraZeneca PLC (NYSE:AZN) for the day (LON:AZN) - August 4 at 9:28 PM logoFTSE 100 surges most in 5 weeks after Bank of England stimulus (LON:AZN) - August 4 at 3:48 PM logo[$$] HSBC hits 6-month high on shareholder payout hopes (LON:AZN) - August 4 at 3:48 PM logoAnalysts Rating Alert: Astrazeneca PLC (NYSE:AZN) , Sophiris Bio, Inc. (NASDAQ:SPHS) - Street Updates (LON:AZN) - August 3 at 12:18 PM logoTwo Movers within Analysts Observation: Astrazeneca PLC (NYSE:AZN) , Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Street Updates (LON:AZN) - August 2 at 8:31 AM logoEdited Transcript of AZN.L earnings conference call or presentation 28-Jul-16 11:00am GMT (LON:AZN) - August 1 at 3:41 PM
News IconJefferies Gives Astrazeneca Price Target With Potential -4.55% Downside (LON:AZN) - July 31 at 3:39 PM logoAstraZeneca PLC (LON:AZN) price target held steady at 5,000GBX as covered today by Exane BNP Paribas (LON:AZN) - July 29 at 9:11 PM logoAstraZeneca PLC (LON:AZN) stock price target maintained at 4,800GBX, reported today by Jefferies International (LON:AZN) - July 29 at 8:37 AM logoAstraZeneca (AZN) Beats on Q2 Earnings, Keeps 2016 View (LON:AZN) - July 29 at 8:37 AM logo3 Biotechs Bouncing on Earnings (LON:AZN) - July 28 at 4:46 PM logoAstraZeneca Slips To Loss In Q2, Revenues Down; Maintains FY Outlook (LON:AZN) - July 28 at 12:28 PM
News IconAstraZeneca Posts $3 Million Loss -- Update (LON:AZN) - July 28 at 12:28 PM logoAstrazeneca beats 2Q profit forecasts (LON:AZN) - July 28 at 12:28 PM logoWhy Analysts Think AstraZeneca’s Revenues Will Fall in 2Q16 (LON:AZN) - July 26 at 9:08 AM
News IconHC Stocks Assessment: Relypsa Inc (NASDAQ:RLYP) AstraZeneca plc (ADR) (NYSE:AZN) - share market updates (press release) (LON:AZN) - July 25 at 9:50 PM
News IconNotable News Recap: AstraZeneca plc (ADR)(NYSE:AZN), U.S. Bancorp(NYSE:USB) - NYSE Journal (press release) (LON:AZN) - July 25 at 9:50 PM logoAstrazeneca PLC (AZN) Shares are Up 2.94% – Trade Calls - Trade Calls (LON:AZN) - July 25 at 9:50 PM logoAnalysts Watch-list Stocks: Astrazeneca PLC (NYSE:AZN) , Novo Nordisk A/S (NYSE:NVO) - Street Updates (LON:AZN) - July 22 at 3:41 PM
News IconAstraZeneca (AZN) Upcoming Earnings: What matter for investors? - The Voice Registrar (LON:AZN) - July 22 at 11:54 AM logoGalenica to buy biotech firm Relypsa for $1.5 bln, ahead of split (LON:AZN) - July 21 at 4:30 AM logoAstraZeneca gets EU approval for Qtern (LON:AZN) - July 19 at 9:05 PM logoAstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint (LON:AZN) - July 19 at 9:05 PM


Last Updated on 8/31/2016 by Staff